People seem to be forgetting this is an exploratory study and is designed to generate data around the mechanisms of iPPS in vivo. PAR really just need to take this data to the FDA to get an agreement on DMOAD and then to examine it as part of a formal hypothesis in PARA 003.
OA is a multimodal disease that IMO requires the totality of effects to be considered, not just single endpoints.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381039&isReview=true
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-52
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $133.5K | 434.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12472 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 1298 | 3 |
View Market Depth
| Last trade - 14.50pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |